11.61
+0.2(+1.75%)
Currency In USD
| Previous Close | 11.41 |
| Open | 11.41 |
| Day High | 11.99 |
| Day Low | 11.01 |
| 52-Week High | 27.5 |
| 52-Week Low | 4.81 |
| Volume | 275,244 |
| Average Volume | 318,345 |
| Market Cap | 388.06M |
| PE | -5.28 |
| EPS | -2.2 |
| Moving Average 50 Days | 11.1 |
| Moving Average 200 Days | 14.65 |
| Change | 0.2 |
If you invested $1000 in MBX Biosciences, Inc. Common Stock (MBX) since IPO date, it would be worth $490.91 as of July 02, 2025 at a share price of $11.61. Whereas If you bought $1000 worth of MBX Biosciences, Inc. Common Stock (MBX) shares 0 years ago, it would be worth $490.91 as of July 02, 2025 at a share price of $11.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
GlobeNewswire Inc.
Jun 23, 2025 12:00 PM GMT
Dr. Moraitis brings deep experience in endocrinology to his role leading clinical development for MBX’s lead product candidate, canvuparatideCARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage bioph
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE)
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
GlobeNewswire Inc.
Jun 10, 2025 12:00 PM GMT
CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabol